Investing in stocks inevitably means buying into some companies that perform poorly. But the last three years have ...

Deal to acquire OxyChem for $9.7-billion could mark Buffett’s last big deal before he hands over the reins to Greg Abel in ...

OpenText looks cheap and yields about 3%, but heavy debt and a recent profit slump make it a turnaround play for patient ...

Awarded contract base period of US$3.6 million to fund vaccine manufacturing with additional option periods to advance development through Phase 1 trials. Submitted up to US$97 mi ...